Introduction: Serological testing in SARS-CoV-2 infection is gaining both patients' and clinicians' attention Antibody assessment has potential multidirectional utility, hampered by the scarcity of clinical validation studies of the tests available on the market Therefore, this study aimed to provide some evidence on the clinical utility of anti-SARS-CoV-2 commercial assays, based on the comparison of the results obtained with different methods Material and methods: The study included 52 samples from patients and healthy volunteers The control samples (n = 20) were obtained during the SARS-CoV-2 pandemic The case cohort consisted of 32 consecutive patients referred to the Diagnostyka medical laboratory for anti-SARS-CoV-2 antibody testing For the purpose of this study, the MAGLUMI chemiluminescent immunoassay (CLIA) was chosen as a comparative method All samples were tested with this method, as well as with the Euroimmun enzyme-linked immunosorbent assay (ELISA) and five different lateral flow immunoassays (LFIAs)
A comparison of 7 commercial anti-SARS-CoV-2 antibody immunoassays